Natural Products for the Prevention and Control of the COVID-19 Pandemic: Sustainable Bioresources

Singla, Rajeev K.; He, Xiao Shun; Chopra, Hitesh; Tsagkaris, Christos; Shen, Li; Kamal, Mohammad Amjad; Shen, Bairong

doi:10.3389/fphar.2021.758159

Cited by 28 publications

(23 citation statements)

References 339 publications

(371 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, kaempferol has been isolated from various other sources including Euonymus alatus (Thunb.) Siebold ( Fang et al, 2008 ; Singla et al, 2021 ), Vachellia nilotica (L.) P.J.H.Hurter and Mabb. ( Singh et al, 2008 ), etc, with multiple therapeutic potential, including but not limited to antiproliferative ( Park et al, 2021 ), antiviral ( Arabyan et al, 2021 ), hepatoprotective ( Alshehri et al, 2021 ), antioxidant ( Sharma et al, 2021 ), etc.…”

Section: Introductionmentioning

confidence: 99%

The Genus Alternanthera: Phytochemical and Ethnopharmacological Perspectives

et al. 2022

Self Cite

View full text Add to dashboard Cite

Ethnopharmacological relevance: The genus Alternanthera (Amaranthaceae) comprises 139 species including 14 species used traditionally for the treatment of various ailments such as hypertension, pain, inflammation, diabetes, cancer, microbial and mental disorders.Aim of the review: To search research gaps through critical assessment of pharmacological activities not performed to validate traditional claims of various species of Alternanthera. This review will aid natural product researchers in identifying Alternanthera species with therapeutic potential for future investigation.Materials and methods: Scattered raw data on ethnopharmacological, morphological, phytochemical, pharmacological, toxicological, and clinical studies of various species of the genus Alternanthera have been compiled utilizing search engines like SciFinder, Google Scholar, PubMed, Science Direct, and Open J-Gate for 100 years up to April 2021.Results: Few species of Alternanthera genus have been exhaustively investigated phytochemically, and about 129 chemical constituents related to different classes such as flavonoids, steroids, saponins, alkaloids, triterpenoids, glycosides, and phenolic compounds have been isolated from 9 species. Anticancer, antioxidant, antibacterial, CNS depressive, antidiabetic, analgesic, anti-inflammatory, and immunomodulator effects have been explored in the twelve species of the genus. A toxicity study has been conducted on 3 species and a clinical study on 2 species.Conclusions: The available literature on pharmacological studies of Alternanthera species reveals that few species have been selected based on ethnobotanical surveys for scientific validation of their traditional claims. But most of these studies have been conducted on uncharacterized and non-standardized crude extracts. A roadmap of research needs to be developed for the isolation of new bioactive compounds from Alternanthera species, which can emerge out as clinically potential medicines.

show abstract

Section: Introductionmentioning

confidence: 99%

The Genus Alternanthera: Phytochemical and Ethnopharmacological Perspectives

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Intriguingly, natural products are one of the most promising therapies for a broad spectrum of refractory diseases including coronavirus disease 2019 and its complications ( Chen et al, 2018a ; Chen et al, 2018b ; Izzo et al, 2020 ; Yang et al, 2021a ; Yang et al, 2021b ; Zhang et al, 2021b ; Singla et al, 2021 ; Zuo et al, 2021 ). Mounting natural products have been demonstrated to exhibit excellent efficacy for CKD treatment ( Wang et al, 2018b ; Zhang et al, 2020c ; Geng et al, 2020 ; Meng et al, 2020 ; Miao et al, 2020 ; Lan, 2021 ; Li et al, 2021 ; Luo et al, 2021 ; Miao et al, 2022 ; Yu et al, 2022 ).…”

Section: Treatment Of Membranous Nephropathymentioning

confidence: 99%

Recent Advances in Clinical Diagnosis and Pharmacotherapy Options of Membranous Nephropathy

et al. 2022

View full text Add to dashboard Cite

Membranous nephropathy (MN) is the most common cause of nephrotic syndrome among adults, which is the leading glomerular disease that recurs after kidney transplantation. Treatment for MN remained controversial and challenging, partly owing to absence of sensitive and specific biomarkers and effective therapy for prediction and diagnosis of disease activity. MN starts with the formation and deposition of circulating immune complexes on the outer area in the glomerular basement membrane, leading to complement activation. The identification of autoantibodies against the phospholipase A2 receptor (PLA2R) and thrombospondin type-1 domain-containing protein 7A (THSD7A) antigens illuminated a distinct pathophysiological rationale for MN treatments. Nowadays, detection of serum anti-PLA2R antibodies and deposited glomerular PLA2R antigen can be routinely applied to MN. Anti-PLA2R antibodies exhibited much high specificity and sensitivity. Measurement of PLA2R in immune complex deposition allows for the diagnosis of PLA2R-associated MN in patients with renal biopsies. In the review, we critically summarized newer diagnosis biomarkers including PLA2R and THSD7A tests and novel promising therapies by using traditional Chinese medicines such as Astragalus membranaceus, Tripterygium wilfordii, and Astragaloside IV for the treatment of MN patients. We also described unresolved questions and future challenges to reveal the diagnosis and treatments of MN. These unprecedented breakthroughs were quickly translated to clinical diagnosis and management. Considerable advances of detection methods played a critical role in diagnosis and monitoring of treatment.

show abstract

“…31 Current research into drugs to treat COVID-19 includes peptides, antibodies, natural products, drug repurposing, as well as the synthesis of new molecules. 32 , 33 , 34 In drug discovery programs, small molecules as therapeutics agents have an important role because of economic limitations. Various small molecules are reported as inhibitors of SARS-CoV-2 entry [i.e., of S proteins (S1/S2/RBD) and ACE2 (RBD/ACE2 interface)].…”

Section: Mutations In the Target Site Of The S Pro...mentioning

confidence: 99%